Medifast, Inc.

NYSE:MED

Personal Products & Services

Consumer Cyclical
$12.20 -0.04%

-$0.01 today

Market cap
$136.43M
Beta
0.66
P/E (TTM)
-6.2
EPS (TTM)
-$1.82
52W Low $9.22High $15.46

Volume 0.09M

Average 0.21M

MED Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Medifast, Inc.NYSE: MED

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $3.48M rose 6.2% year over year, behind the +13.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.

Context

  • Depreciation & amortization amounted to 3.7% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +6.2% toward the trailing-twelve-month pace of +13.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.48M+0.5% QoQ
Last fiscal yearDec 2025
$14.24M-18.1% YoY
LTMMar 2026
$14.45M+13.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.2%——
1 year-18.1%——
3-year CAGR+9.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
14.24M USD
Year-over-year change
-18.1%
4-year CAGR
+20.2%

Depreciation & Amortization vs competitors

How MED compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.5% is the 2nd highest of 10, against a peer median of -7.5%.
  • Depreciation & amortization amounts to 4.2% of revenue for MED, versus a peer median of 3.2%.
MED Competitors
Depreciation & Amortization for MED and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MBMasterBeef GroupFY2025HK$66.6M HKD-15.3%-1.0%14.5%
CURVTorrid Holdings Inc.LTM May 2026$31.4M USD-35.8%-25.1%3.2%
CAASChina Automotive Systems, Inc.LTM Jun 2025$18.62M USD-7.0%-17.3%2.7%
AKAa.k.a. Brands Holding Corp.LTM Mar 2026$18.13M USD+2.6%-25.7%3.0%
MEDMedifast, Inc.LTM Mar 2026$14.45M USD+13.5%+9.1%4.2%
CLARClarus CorporationLTM Mar 2026$12.2M USD-9.3%-18.6%4.8%
BSETBassett Furniture Industries, IncorporatedLTM Feb 2026$8.79M USD-7.5%-4.3%2.6%
KEQUKewaunee Scientific CorporationLTM Jan 2026$6.3M USD+57.4%+19.8%2.2%
DIBS1stdibs.Com, Inc.LTM Mar 2026$5.32M USD-2.7%+0.3%5.9%
AIIORobo.ai Inc.FY2025$1.6M USD-54.8%+28.9%168.6%
Peer median (excluding MED) —-7.5%-4.3%3.2%

Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income164.03M143.57M99.42M2.09M(18.67M)
Depreciation & Amortization6.81M10.98M13.11M17.4M14.24M
Deferred Income Tax(3.72M)(924K)1.21M(7.4M)11.46M
Stock-Based Compensation9.9M11.05M8.19M7.36M7.64M
Change in Working Capital(87.65M)21.65M20.28M(9.75M)(9.81M)
Accounts Receivables00000
Inventory(126.65M)61.19M64.27M12.17M22.19M
Accounts Payables54.38M(37.59M)(35.71M)(34.99M)(23.91M)
Other Working Capital39.01M(1.94M)(8.28M)13.08M(8.09M)
Other Non-Cash Items5.16M8.24M5.46M14.77M2M
Operating Cash Flow94.55M194.57M147.66M24.48M6.86M
Capital Expenditures(34.21M)(16.68M)(6.48M)(7.45M)(5.61M)
Acquisitions (Net)00000
Purchases of Investments00(54.56M)(46.6M)(84.41M)
Sales of Investments5.15M5.27M027.43M78.78M
Other Investing Activities00095K3.31M
Investing Cash Flow(29.06M)(11.41M)(61.05M)(26.52M)(7.93M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased(62.09M)(127.96M)(6.96M)(836K)(369K)
Dividends Paid(63.86M)(71.62M)(73.02M)(715K)(195K)
Other Financing Activities811K0188K36K0
Financing Cash Flow(125.13M)(199.58M)(79.79M)(1.52M)(564K)
Effect of Forex Changes112K(67K)(72K)47K4K
Net Change in Cash(59.54M)(16.49M)6.75M(3.51M)(1.63M)
Free Cash Flow60.34M177.89M141.17M17.02M1.25M

Medifast, Inc.

NYSE:MED

Intrinsic Alpha fair value

Locked

Current Price

$12.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.